Clinical Trial Update: Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study of gevokizumab for Pyoderma gangrenosum has completed, sponsored by XOMA (US) LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• Gevokizumab (gevokizumab)

Snippet

Sponsor: XOMA (US) LLC | Conditions: Pyoderma Gangrenosum | Phase 2 | Status: COMPLETED